Barclays analyst Sidhartha Modi maintained a Buy rating on Sandoz Group Ltd today and set a price target of CHF55.00. The company’s shares closed last Thursday at $61.11.Elevate Your Investing Strategy:...
Novartis is gaining traction this year, but can the trend continue?
Expands access to much-needed iron therapy for millions of US patients Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches ...
For Immediate ReleaseChicago, IL – June 10, 2025 – Today, Zacks Equity Research discusses Sandoz SDZNY, Teva Pharmaceuticals TEVA and Viatris VTRS.Industry: Generic DrugsLink: https://www.zacks.com/commentary/2490523/3-generic-drug-stocks-to-watch-amid-pricing-pressure-tariff-threatsGeneric...
Generic drugmakers continue to face mounting pressure not only from pricing competition but also from Trump’s push for pharmaceutical import tariffs and the proposed “most-favored-nation” pricing...
For Immediate ReleaseChicago, IL – April 16, 2025 – Today, Zacks Equity Research Equity are Dr. Reddy’s Laboratories RDY, Sandoz SDZNY and Teva Pharmaceuticals TEVA.Industry: Generic DrugsLink: https://www.zacks.com/commentary/2448907/3-generic-drug-stocks-to-watch-amid-trade-war-jitters-inflation-woesWhile...
While 2025 began on a positive note for the pharmaceutical industry, things have taken a sharp turn amid escalating fears of a global trade war. While Trump had initially exempted pharmaceuticals from...
Intra-Cellular Therapies ITCI signed a definitive agreement with pharma bigwig Johnson & Johnson JNJ. Per the terms, the pharma giant will acquire all outstanding shares of ITCI for $132 per share in cash,...
Coherus is divesting its non-core ophthalmology franchise.
Eli Lilly, McKesson, and Novartis are catching investors' attention with promising chart patterns and revenue growth, signaling potential buying opportunities.